Name | CNQX disodium salt |
---|---|
Synonyms |
Disodium 6-cyano-7-nitro-2,3-quinoxalinediolate
disodium 6-cyano-7-nitroquinoxaline-2,3-diolate 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-, sodium salt (1:2) |
Description | CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist[1]. CNQX disodium blocks the expression of fear-potentiated startle in rats[5]. |
---|---|
Related Catalog | |
Target |
IC50: 0.3 μM (AMPA) and 1.5 μM (kainate receptor)[1] |
In Vitro | CNQX disodium (FG9065 disodium; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices[2]. CNQX disodium (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments[3]. |
In Vivo | CNQX disodium (FG9065 disodium; 0.75-3 mg/kg; IP; 20 min before testing) decreased the number of cocaine responses in a dose-dependent manner during the first 15-min cocaine-free interval[4]. The bilateral infusion of CNQX disodium (0.5 or 1.25 μg) into the amygdala or dorsal hippocampus 10 min prior to a retention test partially blocks the expression of stepdown inhibitory avoidance in rats 24 h after training. CNQX disodium causes a complete blockade at a dose of 0.5 μg[5]. Animal Model: Male Wistar rats weighing 180-200 g[4] Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval. |
References |
Molecular Formula | C9H2N4Na2O4 |
---|---|
Molecular Weight | 276.116 |
Exact Mass | 275.987152 |